Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK

Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specif...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Cancer 2016-01, Vol.7 (11), p.1383-1387
Main Authors: Damm-Welk, Christine, Siddiqi, Faraz, Fischer, Matthias, Hero, Barbara, Narayanan, Vignesh, Camidge, David Ross, Harris, Michael, Burke, Amos, Lehrnbecher, Thomas, Pulford, Karen, Oschlies, Ilske, Siebert, Reiner, Turner, Suzanne, Woessmann, Wilhelm
Format: Article
Language:English
Subjects:
Short Research Communication
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK.
ISSN:1837-9664
1837-9664
DOI:10.7150/jca.15238